ImmunityBio, Inc. IBRX Reportable Segment — Other research and development costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept ibrx:ResearchAndDevelopmentExpenseInternalOtherCosts.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s reportable segment — other research and development costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s reportable segment — other research and development costs?
- ImmunityBio, Inc. (IBRX) reported reportable segment — other research and development costs of $8.47M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — other research and development costs changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — other research and development costs increased by 31.0% year-over-year, from $6.47M to $8.47M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — other research and development costs?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — other research and development costs has grown at a 32.0% compound annual growth rate (CAGR), from $24.35M to $42.43M.
- What does reportable segment — other research and development costs mean?
- Encompasses miscellaneous research and development expenses not categorized as internal personnel or external contract costs. This may include laboratory supplies, software licenses, and regulatory filing fees.